Nexavar as first targeted therapy in patients with advanced renal cell carcinoma (NEXTAR)
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
- Patients with a diagnosis of advanced Renal cell carcinoma (RCC) for whom the decision has been taken by the investigator to prescribe Nexavar. - Patients who failed cytokine therapy or who are not suitable for cytokines for whom Nexavar is the first targeted drug treatment.
- Prior targeted therapy for RCC - Contraindications of Nexavar described in the Summary of Product Characteristics (SPC).
Many Locations, Germany
E-mail: [email protected]
Phone: Not Available
NEXTAR - NEXavar® as first TARgeted treatment for patients with advanced Renal Cell Carcinoma